Aurora Receives Initially Approval for Medicinal Cannabis Item in Ireland – Cannabis News | Life-style Strategies | Professional Opinions




EDMONTON, Dec. two, 2019 /CNW/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE │ TSX: ACB), the Canadian corporation defining the future of cannabis worldwide, currently announced that a single of the Company’s oil goods has now been authorized for use beneath Ireland’s new Health-related Cannabis Access Programme (MCAP). Aurora’s Higher CBD Oil Drops received approval from the Irish authorities and has now been added to a regulatory schedule by the Irish Minister of Well being enabling importation, prescribing and provide beneath the scheme and is to date, a single of only two goods to get such authorization.

Dr. Shane Morris, Chief Item Officer at Aurora mentioned, “Aurora is pleased to be capable to help individuals who are looking for therapy with higher-good quality EU-GMP (excellent manufacturing practice) certified pharmaceutical-grade healthcare cannabis in Ireland.   We are pretty proud to be a single of the 1st authorized suppliers of healthcare cannabis beneath the MCAP.  We want to acknowledge the efforts created by several individuals, in particular the individuals and physicians who have campaigned for access to these medicines.  We appear forward to much more of Aurora’s higher-good quality medicines getting authorized so that much more individuals can advantage from the MCAP in Ireland.  We will continue to perform closely with all parties and state agencies to facilitate additional availability.”

Beneath the new plan, a consultant can prescribe healthcare cannabis for individuals beneath their care who have any of the following healthcare circumstances:

·         Spasticity related with various sclerosis 

·         Intractable nausea and vomiting related with chemotherapy 

·         Severe, refractory (therapy-resistant) epilepsy

The Health-related Cannabis Access Programme was signed into law in June 2019 by Ireland’s Minister for Well being, Simon Harris. The plan will facilitate access to cannabis-primarily based healthcare goods in line with legislation and is scheduled to run for five years.

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 nations across 5 continents, Aurora is a single of the world’s biggest and major cannabis businesses. Aurora is vertically integrated and horizontally diversified across each essential segment of the worth chain, from facility engineering and design and style to cannabis breeding and genetics study, cannabis and hemp production, derivatives, higher worth-add item improvement, house cultivation, wholesale and retail distribution.

Hugely differentiated from its peers, Aurora has established a uniquely sophisticated, constant and effective production approach, primarily based on goal-constructed facilities that integrate major-edge technologies across all processes, defined by in depth automation and customization, resulting in the enormous scale production of a higher-good quality constant item. Made to be replicable and scalable globally, our production facilities are created to generate cannabis at a important scale, with higher good quality, market-major yields, and low-per gram production charges. Each and every of Aurora’s facilities is constructed to meet European Union Fantastic Manufacturing Practices (“EU GMP”) requirements. Certification has been granted to Aurora’s 1st production facility in Mountain View County, the MedReleaf Markham facility, and its wholly-owned European healthcare cannabis distributor Aurora Deutschland. All Aurora facilities are created and constructed to the EU GMP normal.

In addition to the Company’s speedy organic development and sturdy execution on strategic M&ampA, which to date involves 17 wholly-owned subsidiary businesses – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco – Aurora is distinguished by its reputation as a companion and employer of decision in the international cannabis sector, getting invested in and established strategic partnerships with a variety of major innovators, like Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), Higher Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).

Terry Booth, CEO        
Aurora Cannabis Inc.   

Supply Aurora Cannabis Inc.



Latest posts